Cargando…
New paradigms for the treatment of lysosomal storage diseases: targeting the endocannabinoid system as a therapeutic strategy
Over the past three decades the lysosomal storage diseases have served as model for rare disease treatment development. While these efforts have led to considerable success, important challenges remain. For example, no treatments are currently approved for nearly two thirds of all lysosomal diseases...
Autores principales: | Schuchman, Edward H., Ledesma, Maria D., Simonaro, Calogera M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992818/ https://www.ncbi.nlm.nih.gov/pubmed/33766102 http://dx.doi.org/10.1186/s13023-021-01779-4 |
Ejemplares similares
-
Polyarticular arthritis as presenting feature of farber disease: a lysosomal storage disease involving inflammation
por: Sólyom, Alexander, et al.
Publicado: (2014) -
Efficacy of pentosan polysulfate in in vitro models of lysosomal storage disorders: Fabry and Gaucher Disease
por: Crivaro, Andrea N., et al.
Publicado: (2019) -
Acid Ceramidase Protects Against Hepatic Ischemia/Reperfusion Injury by Modulating Sphingolipid Metabolism and Reducing Inflammation and Oxidative Stress
por: Jiang, Yuan, et al.
Publicado: (2021) -
Enhanced chondrocyte apoptosis leads to abnormal cartilage in rats and cats with glycosaminoglycan storage diseases
por: Simonaro, CM, et al.
Publicado: (2001) -
Anti-TNF-Alpha Therapy Enhances the Effects of Enzyme Replacement Therapy in Rats with Mucopolysaccharidosis Type VI
por: Eliyahu, Efrat, et al.
Publicado: (2011)